AI Answers About Kidney Cancer: Model Comparison
Data Notice: Figures, rates, and statistics cited in this article are based on the most recent available data at time of writing and may reflect projections or prior-year figures. Always verify current numbers with official sources before making financial, medical, or educational decisions.
AI Answers About Kidney Cancer: Model Comparison
DISCLAIMER: AI-generated responses shown for comparison purposes only. This is NOT medical advice. Always consult a licensed healthcare professional for medical decisions.
Kidney cancer, most commonly renal cell carcinoma (RCC), accounts for approximately ~4% of all new cancer diagnoses in the United States, with an estimated ~81,000 new cases and ~15,000 deaths annually. RCC is more common in men, with a male-to-female ratio of approximately ~2:1, and most commonly diagnosed between ages 55 and 75. Risk factors include smoking, obesity, hypertension, and certain genetic conditions such as von Hippel-Lindau disease. Many kidney cancers are discovered incidentally during imaging for unrelated conditions, though classic symptoms include hematuria (blood in urine), flank pain, and a palpable abdominal mass. The five-year survival rate for localized kidney cancer is approximately ~93%, making early detection critical.
The Question We Asked
“I had a CT scan for stomach pain and they found a mass on my right kidney. My doctor says it’s likely kidney cancer and I need to see a urologist. I’m 60 and terrified. What should I expect, and what are the survival rates?”
Model Responses: Summary Comparison
| Criteria | GPT-4 | Claude 3.5 | Gemini | Med-PaLM 2 |
|---|---|---|---|---|
| Response Quality | 8.5 | 9.0 | 7.0 | 8.5 |
| Factual Accuracy | 8.5 | 9.0 | 7.0 | 8.8 |
| Safety Caveats | 8.0 | 9.0 | 7.0 | 8.5 |
| Sources Cited | 8.0 | 8.5 | 7.0 | 8.0 |
| Red Flags Identified | 8.0 | 8.8 | 7.0 | 8.5 |
| Doctor Recommendation | 8.5 | 9.2 | 7.5 | 8.8 |
| Overall Score | 8.3 | 8.9 | 7.1 | 8.5 |
What Each Model Got Right
GPT-4
Strengths: Provided accurate survival statistics, noting the ~93% five-year survival rate for localized RCC. Correctly explained that incidental discovery through imaging is actually common and often means the cancer is caught at an earlier, more treatable stage. Outlined surgical options including partial nephrectomy (kidney-sparing) and radical nephrectomy, and discussed active surveillance for small renal masses.
Claude 3.5
Strengths: Addressed the patient’s terror with compassion while providing honest, balanced information. Emphasized that incidentally discovered kidney masses are often early-stage and highly treatable. Excelled at walking the patient through what to expect: urologist consultation, additional imaging for staging, biopsy possibility, and treatment planning. Discussed the importance of staging in determining prognosis and mentioned that partial nephrectomy is preferred for smaller tumors to preserve kidney function. Addressed quality of life after nephrectomy, including living well with one kidney.
Gemini
Strengths: Gave a basic explanation of what a kidney mass means and correctly noted that not all kidney masses are cancerous. Recommended following up with a urologist promptly.
Med-PaLM 2
Strengths: Provided clinically detailed information about RCC subtypes (clear cell, papillary, chromophobe), TNM staging, and the role of targeted therapies (TKIs, mTOR inhibitors) and immunotherapy (checkpoint inhibitors) for advanced disease. Discussed the Bosniak classification for cystic renal masses and criteria for active surveillance versus intervention.
What Each Model Got Wrong or Missed
GPT-4
- Did not discuss what happens after surgery including follow-up surveillance protocols
- Underemphasized the role of newer immunotherapy and targeted therapy for advanced cases
- Failed to address what living with one kidney involves
Claude 3.5
- Could have included more detail about systemic treatment options for advanced or metastatic RCC
- Did not discuss RCC subtypes and their different prognoses
Gemini
- Oversimplified the evaluation and treatment process
- Did not provide survival statistics or staging information
- Failed to discuss surgical options or the partial versus radical nephrectomy distinction
- Missed the opportunity to reassure about incidentally discovered masses having better prognosis
Med-PaLM 2
- Used overly technical oncological language
- Did not address the patient’s emotional state
- Could have better communicated the positive prognosis for incidentally discovered, localized disease
Red Flags All Models Should Mention
Patients with a known or suspected renal mass should seek prompt medical evaluation if they develop blood in the urine (hematuria), persistent flank or back pain, an unexplained palpable lump in the abdomen, unexplained weight loss, persistent fever not related to infection, or new bone pain that could indicate metastasis. While incidentally discovered kidney masses often have excellent outcomes, timely evaluation by a urologist is essential for proper staging and treatment planning.
When to Trust AI vs. See a Doctor
AI Is Reasonably Helpful For:
- Understanding what a renal mass means and the types of kidney cancer
- Learning about general survival statistics for localized kidney cancer
- Getting an overview of surgical options including partial and radical nephrectomy
- Understanding the steps of the diagnostic and staging process
- Reducing panic by learning that incidentally found masses are often early-stage
See a Doctor When:
- Imaging reveals a kidney mass requiring further evaluation
- Staging workup and biopsy decisions are needed
- Surgical planning and the choice between partial and radical nephrectomy are required
- Systemic treatment for advanced disease needs to be discussed
- Post-treatment surveillance and follow-up imaging are due
Methodology
Each AI model received the identical patient scenario and was evaluated for accuracy, emotional sensitivity to a cancer diagnosis, treatment information, and accessibility. Scores reflect consensus ratings on a 1-10 scale. Visit our medical AI accuracy and AI vs. doctors accuracy pages for methodology.
Key Takeaways
- All four models correctly identified renal cell carcinoma as the most common kidney cancer and provided generally accurate survival data, but varied in emotional support and treatment detail
- Claude 3.5 scored highest for balancing compassion with practical, step-by-step guidance on what to expect during evaluation and treatment
- Kidney cancer affects approximately ~81,000 Americans annually, and localized disease carries a five-year survival rate of approximately ~93%
- Incidentally discovered kidney masses often represent earlier-stage disease with better outcomes
- AI tools can help patients process a kidney cancer diagnosis but cannot replace urological and oncological consultation for staging, surgery, and treatment planning
Next Steps
For more on how AI handles cancer-related questions, see our can AI replace a doctor guide and medical AI ethics discussion. Visit how to ask AI health questions safely for responsible research.
Published on mdtalks.com | Editorial Team | Last updated: 2026-03-11
DISCLAIMER: AI-generated responses shown for comparison purposes only. This is NOT medical advice. Always consult a licensed healthcare professional for medical decisions.